Browse the world's most comprehensive database of hedge fund investor letters, sorted by recent quarter. Access primary source research from leading institutional managers.
| Quarter | Letter Date | Fund Name | QTD | YTD | Tickers | Themes | Quick Take |
|---|---|---|---|---|---|---|---|
Buyside Digest is not affiliated with, and does not endorse, Oakmark International Fund. This analysis is provided for institutional research purposes only and is not investment advice.
"Oakmark International underperformed in Q4 with Airbus driving gains from strong aerospace demand while Bayer weighed on returns due to litigation and guidance concerns. The fund added Korean bank KB Financial and increased Kering exposure despite luxury sector headwinds."
The Oakmark International Fund returned -8.48% in Q4 2024, underperforming the MSCI World ex USA Index by 105 basis points. The portfolio remains concentrated in Europe (71.5%) and UK (15.1%) with emerging markets representing 5.7%. Airbus was the top contributor, benefiting from strong order growth across all divisions and robust demand constrained only by supply capacity. Conversely, Bayer was the largest detractor due to PCB litigation developments and disappointing 2025 guidance, though management's restructuring efforts under new CEO Bill Anderson are expected to drive recovery. The fund added KB Financial Group, South Korea's leading bank, positioned to benefit from the government's value-up program aimed at improving banking sector returns. Luxury goods company Kering faced continued China headwinds, but the managers increased exposure based on margin expansion potential over two to three years. Despite challenging performance in 2024, the managers remain optimistic about mid- to long-term prospects given the quality of holdings and attractive absolute valuations.
Sign in or create a free account to unlock full commentary, extracted equity pitches, and direct outbound manager source links with your 3 quarterly credits.
Algorithmic conviction, macroeconomic posture, and risk appetite signals extracted from this quarterly letter with qualitative explanations.
Market Conviction
The fund demonstrates high conviction through concentrated positioning with named holdings, specific position sizing actions (increasing Kering exposure, adding KB Financial), and detailed multi-year thesis explanations for each major position. However, the presence of hedged language and multiple scenario discussions prevents a higher score.
Growth Outlook
The managers express enthusiasm for mid- to long-term prospects and highlight attractive absolute valuations, but acknowledge challenging periods and sector-specific headwinds like weak China demand affecting luxury goods.
Risk Appetite
The fund increased exposure to existing holdings like Kering and added a new position in KB Financial Group, demonstrating selective risk-taking despite acknowledging current challenges and maintaining concentrated positioning.
Capital Deployment
The fund added one new position (KB Financial Group) and increased exposure to existing holdings like Kering, indicating selective deployment. However, no cash level changes are disclosed and activity appears measured rather than aggressive.
Forward Guidance
Managers are selectively deploying capital with specific additions and increases, showing measured optimism about two to three year recovery potential while watching for confirmatory evidence of success in restructuring stories.
Language Signal
Language is balanced with positive terms like 'enthused,' 'attractive valuations,' and 'quality businesses' offset by acknowledgment of 'challenging periods,' 'headwinds,' and 'poor top-line trends' across multiple holdings.
Perceived Risk
Managers acknowledge specific risks including China demand weakness, PCB litigation uncertainty for Bayer, and geopolitical concerns in South Korea, but these are presented as manageable headwinds rather than systemic threats.
Opportunity Density
The managers highlight attractive absolute valuations across holdings and identify specific opportunities like KB Financial at compelling valuations and Kering's margin expansion potential, suggesting a reasonably rich opportunity set despite sector challenges.
Time Horizon
The fund explicitly discusses two to three year recovery timelines for Kering margins, multi-year restructuring success for Bayer, and long-term prospects for the overall portfolio, demonstrating a patient, multi-year investment approach with minimal catalyst dependency.
